NOD2 Responds to Dengue Virus Type 2 Infection in Macrophage-like Cells Interacting with MAVS Adaptor and Affecting IFN-α Production and Virus Titers.
Diana Alhelí Domínguez-MartínezMayra Silvia Pérez-FloresDaniel Núñez-AvellanedaJesús M Torres-FloresGloria León-AvilaBlanca Estela García-PérezMa Isabel Salazar-SanchezPublished in: Pathogens (Basel, Switzerland) (2024)
In pathogen recognition, the nucleotide-binding domain (NBD) and leucine rich repeat receptors (NLRs) have noteworthy functions in the activation of the innate immune response. These receptors respond to several viral infections, among them NOD2, a very dynamic NLR, whose role in dengue virus (DENV) infection remains unclear. This research aimed to determine the role of human NOD2 in THP-1 macrophage-like cells during DENV-2 infection. NOD2 levels in DENV-2 infected THP-1 macrophage-like cells was evaluated by RT-PCR and Western blot, and an increase was observed at both mRNA and protein levels. We observed using confocal microscopy and co-immunoprecipitation assays that NOD2 interacts with the effector protein MAVS (mitochondrial antiviral signaling protein), an adaptor protein promoting antiviral activity, this occurring mainly at 12 h into the infection. After silencing NOD2 , we detected increased viral loads of DENV-2 and lower levels of IFN-α in supernatants from THP-1 macrophage-like cells with NOD2 knock-down and further infected with DENV-2, compared with mock-control or cells transfected with Scramble-siRNA. Thus, NOD2 is activated in response to DENV-2 in THP-1 macrophage-like cells and participates in IFN-α production, in addition to limiting virus replication at the examined time points.
Keyphrases
- dengue virus
- zika virus
- immune response
- aedes aegypti
- innate immune
- adipose tissue
- binding protein
- dendritic cells
- protein protein
- sars cov
- induced apoptosis
- endothelial cells
- oxidative stress
- south africa
- toll like receptor
- small molecule
- inflammatory response
- cell proliferation
- drug delivery
- protein kinase
- cancer therapy
- pi k akt